Status:
COMPLETED
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma
Lead Sponsor:
Cancer Foundation, China
Collaborating Sponsors:
Pfizer
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
Brief Summary
This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies. The aim of the trial is to increase k...
Detailed Description
Because State Food and Drug Administration (SFDA) exempted manufacturers from conducting clinical trials of Sunitinib in China, overall efficacy and safety data of Sunitinib in Chinese patients with r...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed, unresectable advanced renal cell carcinoma;
- Sunitinib as first-line treatment alone or combined with other therapies.
Exclusion
- History of Grade 3/4 severe allergic reaction to Sunitinib or its metabolites
Key Trial Info
Start Date :
November 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT01441661
Start Date
November 1 2007
End Date
June 1 2012
Last Update
March 18 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
2
Tongji Hospital, Tongji Medical College of Hust
Wuhan, Hubei, China, 430030